$105.34+0.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
The quarter ending June 30, 2024, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2024 | 3 months toJun 30, 2023 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Oruka Therapeutics, Inc. reported on November 9, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The second quarter and recent months were highly productive as we advanced both of our co-lead programs toward a series of important readouts,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Oruka Therapeutics, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.